News
Bio Boston 2023
AQS Bio will attend Bio Boston from June 5-8, 2023
Global Licensing Agreement Expansion
AQS Bio becomes the first consulting company to assist with one of the first Global Licensing Agreement expansions, between a Japanese biopharma and a top 15 Chinese biopharma, for a novel clinical stage obesity asset.
Consulting Services Company First
AQS Bio becomes the first consulting services company to orchestrate one of the first licensing agreements between a Japanese biopharma and a top 15 Chinese biopharma, for a novel clinical stage obesity asset, for the East Asia territory.
AQS Bio Assists Chinese Insulin Drug EU Approval
AQS Bio assists one of the first Chinese biosimilar companies with an insulin drug approval in the EU.
Top Chinese Biopharma Factory Passes An FDA GMP Inspection
AQS Bio assists a top 10 Chinese biopharma factory with passing an FDA GMP inspection.
Services Delivered For AstraZeneca Shanghai
AQS Bio provides validation assessment and GMP training services for Astra Zeneca, Shanghai China.
Top 10 Chinese Biopharma Company Passes Canadian & US FDA GMP Inspections
AQS Bio becomes the first consulting company to assist a top 10 Chinese biopharma company, one of the first in China, to pass Canadian and US FDA GMP inspections.
A Pre-clinical CRO First
AQS Bio becomes the first consulting company to assist the first pre-clinical CRO to pass the EU OECD inspection in Asia.
